-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Cube Info
On December 21, 3SBio and its partner company, Toray Co.
Hemodialysis patients are often accompanied by complications such as anemia, hypertension, abnormal calcium and phosphorus metabolism, hyperparathyroidism, pruritus, etc.
Nafuraphine hydrochloride is a selective opioid κ receptor agonist independently developed by Toray Co.
In 2009, Nafuraphine Hydrochloride Soft Capsules was approved in Japan to improve pruritus in hemodialysis patients (only if the current treatment effect is not satisfactory), and subsequently, chronic liver disease patients and refractory pruritus in peritoneal dialysis patients Symptoms and other indications have also been approved one after another
The NDA in China is based on the results of a randomized, double-blind, placebo-controlled, multi-center bridging clinical study completed in China
Note: The original text has been deleted